Abstract
Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Graphical Abstract
Current Vascular Pharmacology
Title:Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Volume: 15 Issue: 4
Author(s): Kodappully Sivaraman Siveen, Kirti Prabhu, Roopesh Krishnankutty, Shilpa Kuttikrishnan, Magdalini Tsakou, Feras Q. Alali, Said Dermime, Ramzi M. Mohammad and Shahab Uddin*
Affiliation:
- Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha,Qatar
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Abstract: Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Export Options
About this article
Cite this article as:
Siveen Sivaraman Kodappully , Prabhu Kirti , Krishnankutty Roopesh , Kuttikrishnan Shilpa , Tsakou Magdalini , Alali Q. Feras , Dermime Said , Mohammad M. Ramzi and Uddin Shahab *, Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170105124038
DOI https://dx.doi.org/10.2174/1570161115666170105124038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Lycopene and Cardiovascular Diseases: An Update
Current Medicinal Chemistry Capsule Endoscopy in Crohn’s Disease
Current Drug Targets Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design A Simple and Rapid Method for Expression and Purification of Functional TNF-α Using GST Fusion System
Current Pharmaceutical Biotechnology Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: From Nuisance to State-of-the-Art: FDG-PET/CT Imaging of Infection and Inflammation)
Current Molecular Imaging (Discontinued) Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Current Medicinal Chemistry Rheumatological Diseases in HIV Infection
Current Rheumatology Reviews Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety The Role of Angiotensin in Obesity and Metabolic Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry